Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats metastatic carcinoid tumors. Sold as Sandostatin, Sandostatin Lar, Mycapssa, Bynfezia. Every FDA application for this active ingredient: 4 branded and 23 generic.
As of Nov 16, 2026, FDA lists 27 applications for Octreotide Acetate (sold as Sandostatin, Sandostatin Lar, Mycapssa and others), first approved Oct 21, 1988, with 3 new uses approved and 1 published complete response letter.
First approved: Oct 21, 1988
Applications: 27
New uses approved: 3
Complete response letters: 1
Medicare spending, 2025: $18.9M
Orphan exclusivity until: Jun 26, 2027
First approved in the EU: Dec 2, 2022
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Mycapssa
Part D
$12.8M
+33%
158
Octreotide Acetate
Part D
$5.9M
+5%
3,815
Sandostatin
Part D
$188K
-4%
32
Octreotide Acetate
Part B
$25K
-46%
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
OCTREOTIDE 1,000 MCG/5 ML VIAL: $5.34 per MLGeneric · +1% in a year
[1] SandostatinDrugs with a new additional indication and a new dosage for the treatment of hypoglycemia associated with congenital hyperinsulinism (for use only in… · [1] Novartis Pharma K.K. [2] Sandoz K.K. · Aug 21, 2020
Sandostatin LARDrugs with a new additional indication and a new dosage for the treatment of gastrointestinal neuroendocrine tumor. · Novartis Pharma K.K. · Nov 25, 2011
Clinical Trials
49 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA